Supplementary material from Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers
Year: 2023
Type: supplementary-materials
Abstract: Supplementary methods. Supplementary Table S1. Verification of the analytical sensitivity (lower limit of detection) of the KRASG12/G13 mutation-enrichment NGS assay. Supplementary Table S2. KRASG12/G13 mutations in archival tumor tissue, urine cell-free DNA (cfDNA) and plasma cfDNA. Supplementary Table S3. Systemic therapies in patients with serial urine and/or plasma cell-free DNA (cfDNA) collection. Supplementary Figure S1. Workflow and characteristics of the platform used to analyze cell-free DNA in urine and plasma. Supplementary Figure S2. Schematic of the mutation-enrichment next-generatin sequencing (NGS) assay for the detection of KRASG12/13 mutations in cell-free DNA (cfDNA). Supplementary Figure S2. Schematic of the mutation-enrichment next-generatin sequencing (NGS) assay for the detection of KRASG12/13 mutations in cell-free DNA (cfDNA). Supplementary Figure S3. Kaplan-Meier curves of overall survival (OS) based on the number of KRASG12/13 copies in cell-free DNA (cfDNA). Supplementary Figure S4. Kaplan-Meier curves of overall survival (OS) based on the concentration of cell-free DNA (cfDNA).
Authors: Takeo Fujii, Afsaneh Barzi, Andrea Sartore-Bianchi, Andrea Cassingena, Giulia Siravegna, Daniel D. Karp, Sarina A. Piha-Paul, Vivek Subbiah, Apostolia M. Tsimberidou, Helen J. Huang, Silvio Veronese, Federica Di Nicolantonio, Sandeep Pingle, Cecile Rose T. Vibat, Saege Hancock, David Berz, Vladislava O. Melnikova, Mark G. Erlander, Rajyalakshmi Luthra, E. Scott Kopetz, Funda Meric-Bernstam, Salvatore Siena, Heinz-Josef Lenz, Alberto Bardelli, Filip Janku
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361970358